Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nefecon in primary IgA nephropathy at risk of end-stage renal disease
2012-001923-11Phase 2Completed
- Sponsor
- PharmaLink
- Start
- Aug 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nefecon in IgA nephropathy (IgAN) (3 arms), sponsored by PharmaLink. Primary endpoint: Primary efficacy endpoint. Started Aug 2012; status: completed.
02
Drugs
nefecon
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2012-001923-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001923-11.